Tigecycline for the Treatment of Severe and Severe Complicated Clostridium difficile Infection

Infectious Diseases and Therapy

Volumn 3, Issue 2, 2014, Pages 321-331

  Britt, Nicholas S ^a,b,c   Steed, Molly E ^a   Potter, Emily M ^c   Clough, Lisa A ^b  

^a UNIVERSITY OF KANSAS   (United States)

^b UNIVERSITY OF KANSAS SCHOOL OF MEDICINE   (United States)

^c VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

Clostridium difficile; Combination drug therapy; Tigecycline

Indexed keywords

METRONIDAZOLE; TIGECYCLINE; VANCOMYCIN;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL ASSESSMENT; CLINICAL FEATURE; CLOSTRIDIUM DIFFICILE INFECTION; DIARRHEA; DISEASE SEVERITY; FEMALE; FOLLOW UP; HOSPITALIZATION; HUMAN; LEUKOCYTOSIS; LOADING DRUG DOSE; MALE; MEDICAL RECORD REVIEW; MORTALITY; PROSPECTIVE STUDY; RETROSPECTIVE STUDY; RISK FACTOR; TREATMENT OUTCOME; VERY ELDERLY;

CLOSTRIDIUM DIFFICILE;

EID: 84977124859     PISSN: 21938229     EISSN: 21936382     Source Type: Journal    
DOI: 10.1007/s40121-014-0050-x     Document Type: Article

References (28)

1. Cohen SH, Gerding DN, Johnson S, et al. Clinical practice guidelines for Clostridium difficile infection in adults: 2010 update by the society for healthcare epidemiology of America (SHEA) and the infectious diseases society of America (IDSA). Infect Control Hosp Epidemiol. 2010;31(5):431–55.
2. Moudgal V, Sobel JD. Clostridium difficile colitis: a review. Hosp Pract (1995). 2012;40(1):139–48.
3. Adams SD, Mercer DW. Fulminant Clostridium difficile colitis. Curr Opin Crit Care. 2007;13(4):450–5.
4. Bartlett JG. Narrative review: the new epidemic of Clostridium difficile-associated enteric disease. Ann Intern Med. 2006;145(10):758–64.
5. Centers for Disease Control and Prevention. Antibiotic Resistance Threats in the United States. 2013. p. 55–9. http://www.cdc.gov/drugresistance/threat-report-2013/
6. Loo VG, Poirier L, Miller MA, et al. A predominantly clonal multi-institutional outbreak of Clostridium difficile-associated diarrhea with high morbidity and mortality. N Engl J Med. 2005;353(23):2442–9.
7. Tygacil (tigecycline for injection) [package insert]. Philadelphia: Wyeth Pharmaceuticals, Inc.; 2011.
8. Hawser SP. Activity of tigecycline against recent European clinical isolates of Clostridium difficile. Int J Antimicrob Agents. 2010;35(1):97–8.
9. Nord CE, Sillerstrom E, Wahlund E. Effect of tigecycline on normal oropharyngeal and intestinal microflora. Antimicrob Agents Chemother. 2006;50(10):3375–80.
10. Nagy E, Dowzicky MJ. In vitro activity of tigecycline and comparators against a European compilation of anaerobes collected as part of the Tigecycline Evaluation and Surveillance Trial (TEST). Scand J Infect Dis. 2010;42(1):33–8.
11. Hoffmann M, DeMaio W, Jordan RA, et al. Metabolism, excretion, and pharmacokinetics of [14C]tigecycline, a first-in-class glycylcycline antibiotic, after intravenous infusion to healthy male subjects. Drug Metab Dispos. 2007;35(9):1543–53.
12. Baines SD, Saxton K, Freeman J, Wilcox MH. Tigecycline does not induce proliferation or cytotoxin production by epidemic Clostridium difficile strains in a human gut model. J Antimicrob Chemother. 2006;58(5):1062–5.
13. Jump RL, Li Y, Pultz MJ, Kypriotakis G, Donskey CJ. Tigecycline exhibits inhibitory activity against Clostridium difficile in the colon of mice and does not promote growth or toxin production. Antimicrob Agents Chemother. 2011;55(2):546–9.
14. Lu CL, Liu CY, Liao CH, et al. Severe and refractory Clostridium difficile infection successfully treated with tigecycline and metronidazole. Int J Antimicrob Agents. 2010;35(3):311–2.
15. Lao D, Chiang T, Gomez E. Refractory Clostridium difficile infection successfully treated with tigecycline, rifaximin, and vancomycin. Case Rep Med. 2012;2012:702910.
16. El-Herte RI, Baban TA, Kanj SS. Recurrent refractory Clostridium difficile colitis treated successfully with rifaximin and tigecycline: a case report and review of the literature. Scand J Infect Dis. 2012;44(3):228–30.
17. Herpers BL, Vlaminckx B, Burkhardt O, et al. Intravenous tigecycline as adjunctive or alternative therapy for severe refractory Clostridium difficile infection. Clin Infect Dis. 2009;48(12):1732–5.
18. Marra AR, Edmond MB, Wenzel RP, Bearman GM. Hospital-acquired Clostridium difficile-associated disease in the intensive care unit setting: epidemiology, clinical course and outcome. BMC Infect Dis. 2007;7:42.
19. Miller MA, Louie T, Mullane K, et al. Derivation and validation of a simple clinical bedside score (ATLAS) for Clostridium difficile infection which predicts response to therapy. BMC Infect Dis. 2013;13:148.
20. Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987;40(5):373–83.
21. Crook DW, Walker AS, Kean Y, et al. Fidaxomicin versus vancomycin for Clostridium difficile infection: meta-analysis of pivotal randomized controlled trials. Clin Infect Dis. 2012;55(Suppl 2):S93–103.
22. Cheong EY, Gottlieb T. Intravenous tigecycline in the treatment of severe recurrent Clostridium difficile colitis. Med J Aust. 2011;194(7):374–5.
23. Kopterides P, Papageorgiou C, Antoniadou A, et al. Failure of tigecycline to treat severe Clostridium difficile infection. Anaesth Intensive Care. 2010;38(4):755–8.
24. Garneau JR, Valiquette L, Fortier LC. Prevention of Clostridium difficile spore formation by sub-inhibitory concentrations of tigecycline and piperacillin/tazobactam. BMC Infect Dis. 2014;14:29.
25. Wilcox MH. Evidence for low risk of Clostridium difficile infection associated with tigecycline. Clin Microbiol Infect. 2007;13(10):949–52.
26. Dalm D, Palm GJ, Aleksandrov A, Simonson T, Hinrichs W. Nonantibiotic properties of tetracyclines: structural basis for inhibition of secretory phospholipase A2. J Mol Biol. 2010;398(1):83–96.
27. Yagnik RM, Benzeroual KE. Tigecycline prevents LPS-induced release of pro-inflammatory and apoptotic mediators in neuronal cells. Toxicol In Vitro. 2013;27(2):686–93.
28. Liu MS, Liu CH, Wu G, Zhou Y. Antisense inhibition of secretory and cytosolic phospholipase A2 reduces the mortality in rats with sepsis. Crit Care Med. 2012;40(7):2132–40.